{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:55:21Z","timestamp":1782795321200,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejca.2023.113403","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:17:38Z","timestamp":1698556658000},"page":"113403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Secondary malignancies among mantle cell lymphoma patients"],"prefix":"10.1016","volume":"195","author":[{"given":"Kossi D.","family":"Abalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-467X","authenticated-orcid":false,"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-2027","authenticated-orcid":false,"given":"Simon","family":"Pahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Albertsson-Lindblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113403_bib1","first-page":"2687","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.ejca.2023.113403_bib2","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2019-127863","article-title":"Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma-a randomized European MCL Network Trial","volume":"134","author":"Dreyling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113403_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/10428194.2017.1361024","article-title":"Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma","volume":"59","author":"Parikh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2023.113403_bib4","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2023.113403_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040342","article-title":"Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine","volume":"7","author":"Beeharry","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2023.113403_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.14667","article-title":"Long\u2010term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non\u2010Hodgkin lymphoma","volume":"178","author":"Martin","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2023.113403_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2017-05-737510","article-title":"The potential for chemotherapy-free strategies in mantle cell lymphoma","volume":"130","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113403_bib8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1634\/theoncologist.2017-0470","article-title":"Frontline treatment for older patients with mantle cell lymphoma","volume":"23","author":"Ye","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.113403_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113403_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2021-149600","article-title":"Rituximab-lenalidomide (R2) maintenance is superior to rituximab maintenance after first line immunochemotherapy in mantle cell lymphoma: results of the MCL R2 elderly clinical trial","volume":"138","author":"Ribrag","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113403_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.32391","article-title":"Second primary cancers in non-Hodgkin lymphoma: family history and survival","volume":"146","author":"Chattopadhyay","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.113403_bib12","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2021006369","article-title":"Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study","volume":"6","author":"Joelsson","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2023.113403_bib13","first-page":"3437","article-title":"Second primary malignancies in mantle cell lymphoma: a US population-based study","volume":"35","author":"Shah","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.113403_bib14","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2020.089","article-title":"Increasing incidence of B-cell non-hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-year follow-up using the Korean National Health Information Database","author":"Kim","year":"2020","journal-title":"Cancer Res Treat 52:1262\u20131272"},{"key":"10.1016\/j.ejca.2023.113403_bib15","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","article-title":"Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964\u20132003","volume":"121","author":"Turesson","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.113403_bib16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2023.113403_bib17","unstructured":"Regionala CancerCentrum (RCC) (2022) Nationella kvalitetsregistret f\u00f6r lymfom, diagnosperioden 2000 - 2021."},{"key":"10.1016\/j.ejca.2023.113403_bib18","doi-asserted-by":"crossref","unstructured":"Hoster E. , Dreyling M. , Klapper W. , Gisselbrecht C. , van Hoof A. , Kluin-Nelemans H.C. et al. , German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558\u2013565. https:\/\/doi.org\/10.1182\/blood-2007\u201306-095331.","DOI":"10.1182\/blood-2007-06-095331"},{"key":"10.1016\/j.ejca.2023.113403_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson comorbidity index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2023.113403_bib20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2023.113403_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2023.113403_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0462-x","article-title":"A systematic comparison of recurrent event models for application to composite endpoints","volume":"18","author":"Ozga","year":"2018","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ejca.2023.113403_bib23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2023.113403_bib24","series-title":"Multivariate Analysis of Variance and Repeated Measures: A Practical Approach for Behavioural Scientists","author":"Hand","year":"1987"},{"key":"10.1016\/j.ejca.2023.113403_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2023.113403_bib26","series-title":"Analysing Survival Data from Clinical Trials and Observational Studies","author":"Marubini","year":"1995"},{"key":"10.1016\/j.ejca.2023.113403_bib27","unstructured":"R Core Team (2022) R: A Language and Environment for Statistical Computing."},{"key":"10.1016\/j.ejca.2023.113403_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdf042","article-title":"Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?","volume":"13","author":"Barista","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113403_bib29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113403_bib30","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113403_bib31","doi-asserted-by":"crossref","unstructured":"Tisi M.C. , Moia R. , Patti C. , Evangelista A. , Ferrero S. , Spina M. et al. (2023) Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL. Blood Adv bloodadvances-2023009744.","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"10.1016\/j.ejca.2023.113403_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113403_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-022-00763-0","article-title":"Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders\/diseases","volume":"12","author":"Yu","year":"2022","journal-title":"Cell Biosci"},{"key":"10.1016\/j.ejca.2023.113403_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","article-title":"Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors","volume":"10","author":"Travis","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113403_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ijc.22414","article-title":"Risk of second malignant neoplasms among lymphoma patients with a family history of cancer","volume":"120","author":"Landgren","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.113403_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients \u2013 a nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:44Z","timestamp":1760733824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"alternative-id":["S0959804923007050"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113403","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary malignancies among mantle cell lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113403"}}